

Special Issue

Pharmacovigilance in Drug Therapy and Adverse Reactions

Message from the Guest Editor

Pharmacovigilance is essential for the continuous monitoring of drug safety after marketing authorization has been obtained. This Special Issue, entitled 'Pharmacovigilance in Drug Therapy and Adverse Reactions', aims to highlight recent advances and applications in Pharmacovigilance. Authors are invited to submit original and review articles focusing on three primary areas, namely,

- Pharmacovigilance and Core Artificial Intelligence Technologies (e.g., machine learning, natural language processing and robotic process automation);
- Pharmacovigilance and Biological Medicinal Products (e.g., CAR T-cell therapy, monoclonal antibodies and vaccines);
- Pharmacovigilance and High-Impact Diseases (e.g., cancer, diabetes, cardiovascular and respiratory diseases, neurological and mental disorders and infectious diseases).

We look forward to your valuable contributions.

Guest Editor

Dr. Jaime Conceição

Faculty of Sciences and Technology, University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal

Deadline for manuscript submissions

30 June 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/265366

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)